SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...